Menopausal estrogens and breast cancer. 1976

R Hoover, and L A Gray, and P Cole, and B MacMahon

1891 women given conjugated estrogens for the menopause were followed for 12 years (mean) for incidence of breast cancer. Overall, 49 cases were observed; 39.1 were expected on the basis of rates in the general population (relative risk = 1.3, P = 0.06). The relative risk increased with follow-up duration, progressing to 2.0 after 15 years (13/6.6, P = 0.01). The excess risk after 10 years was not due simply to prolonged estrogen use, since there was no clear dose-response relation to accumulated years of use. However, higher risk accrued to women using higher-dose tablets and those taking the medication on an other than daily basis. In addition, after 10 years of follow-up observation, two factors related to low risk of breast cancer, multiparity and oophorectomy, were no longer so related. Finally, estrogen use was related to an especially high risk of breast cancer among women in whom benign disease developed after they had started the drug.

UI MeSH Term Description Entries
D007629 Kentucky A state bounded on the north by Illinois, Indiana, and Ohio; on the east by Virginia and west Virginia; on the south by Tennessee, and on the west by Missouri.
D008593 Menopause The last menstrual period. Permanent cessation of menses (MENSTRUATION) is usually defined after 6 to 12 months of AMENORRHEA in a woman over 45 years of age. In the United States, menopause generally occurs in women between 48 and 55 years of age. Change of Life, Female
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010298 Parity The number of offspring a female has borne. It is contrasted with GRAVIDITY, which refers to the number of pregnancies, regardless of outcome. Multiparity,Nulliparity,Primiparity,Parity Progression Ratio,Parity Progression Ratios,Ratio, Parity Progression,Ratios, Parity Progression
D001941 Breast Diseases Pathological processes of the BREAST. Endocrine Breast Diseases,Breast Disease,Breast Disease, Endocrine,Breast Diseases, Endocrine,Disease, Breast,Disease, Endocrine Breast,Diseases, Breast,Diseases, Endocrine Breast,Endocrine Breast Disease
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002369 Castration Surgical removal or artificial destruction of gonads. Gonadectomy,Castrations,Gonadectomies
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004966 Estrogens, Conjugated (USP) A pharmaceutical preparation containing a mixture of water-soluble, conjugated estrogens derived wholly or in part from URINE of pregnant mares or synthetically from ESTRONE and EQUILIN. It contains a sodium-salt mixture of estrone sulfate (52-62%) and equilin sulfate (22-30%) with a total of the two between 80-88%. Other concomitant conjugates include 17-alpha-dihydroequilin, 17-alpha-estradiol, and 17-beta-dihydroequilin. The potency of the preparation is expressed in terms of an equivalent quantity of sodium estrone sulfate. Conjugated Equine Estrogen,Conjugated Estrogen,Estrogenic Substances, Conjugated,Progen,Carentil,Climarest,Climopax,Congest,Conjugated Equine Estrogens,Conjugated Estrogens,Dagynil,Estro-Feminal,Estrogenic Hormones, Conjugated,Estrogens, Conjugated,Femavit,Oestro-Feminal,Oestrofeminal,Prelestrin,Premarin,Presomen,Progens,Transannon,Conjugated Estrogenic Hormones,Conjugated Estrogenic Substances,Equine Estrogen, Conjugated,Equine Estrogens, Conjugated,Estro Feminal,Estrogen, Conjugated,Estrogen, Conjugated Equine,Oestro Feminal
D005260 Female Females

Related Publications

R Hoover, and L A Gray, and P Cole, and B MacMahon
December 1987, International journal of cancer,
R Hoover, and L A Gray, and P Cole, and B MacMahon
August 1977, Obstetrics and gynecology,
R Hoover, and L A Gray, and P Cole, and B MacMahon
June 1983, Harefuah,
R Hoover, and L A Gray, and P Cole, and B MacMahon
September 1991, Archives of internal medicine,
R Hoover, and L A Gray, and P Cole, and B MacMahon
January 1997, Salud publica de Mexico,
R Hoover, and L A Gray, and P Cole, and B MacMahon
January 1986, Annals of the New York Academy of Sciences,
R Hoover, and L A Gray, and P Cole, and B MacMahon
November 1976, The New England journal of medicine,
R Hoover, and L A Gray, and P Cole, and B MacMahon
March 1981, Clinical obstetrics and gynecology,
R Hoover, and L A Gray, and P Cole, and B MacMahon
January 2000, Anales de la Real Academia Nacional de Medicina,
R Hoover, and L A Gray, and P Cole, and B MacMahon
January 1984, Revista de la Facultad de Ciencias Medicas (Cordoba, Argentina),
Copied contents to your clipboard!